ABSTRACT
OBJECTIVE: We have carried out a bibliometric study on the scientific publications in relation to atypical or second-generation antipsychotic drugs (SGAs) in South Korea. METHODS: With the EMBASE and MEDLINE databases, we selected those publications made in South Korea whose title included the descriptors atypic* (atypical*) antipsychotic*, second-generation antipsychotic*, clozapine, risperidone, olanzapine, ziprasidone, quetiapine, sertindole, aripiprazole, paliperidone, amisulpride, zotepine, asenapine, iloperidone, lurasidone, perospirone and blonanserin. We applied some bibliometric indicators of paper production and dispersion with Price's law and Bradford's law, respectively. We also calculated the participation index (PI) of the different countries, and correlated the bibliometric data with some social and health data from Korea (such as total per capita expenditure on health and gross domestic expenditure on research and development). RESULTS: We collected 326 original papers published between 1993 and 2011. Our results state fulfilment of fulfilled Price's law, with scientific production on SGAs showing exponential growth (correlation coefficient r=0.8978, as against an r=0.8149 after linear adjustment). The most widely studied drugs were risperidone (91 papers), aripiprazole (77), olanzapine (53), and clozapine (43). Division into Bradford zones yielded a nucleus occupied by the Progress in Neuro-Psychopharmacology and Biological Psychiatry (36 articles). A total of 86 different journals were published, with 4 of the first 10 used journals having an impact factor being greater than 4. CONCLUSION: The publications on SGAs in South Korea have undergone exponential growth over the studied period, without evidence of reaching a saturation point.
Subject(s)
Antipsychotic Agents , Benzodiazepines , Biological Psychiatry , Bipolar Disorder , Clozapine , Complement Factor B , Dibenzothiazepines , Dibenzothiepins , Health Expenditures , Heterocyclic Compounds, 4 or More Rings , Imidazoles , Indoles , Isoindoles , Isoxazoles , Jurisprudence , Korea , Piperazines , Piperidines , Pyrimidines , Quinolones , Republic of Korea , Risperidone , Schizophrenia , Subject Headings , Sulpiride , Thiazoles , Quetiapine Fumarate , Aripiprazole , Lurasidone HydrochlorideABSTRACT
Psychopharmacology has developed over approximately the past five decades. The remarkable proliferation of information in this area has made it difficult for clinicians to understand the characteristics of various psychotropic agents. Atypical antipsychotics including amisulpride, asenapine, aripiprazole, blonanserin, clozapine, iloperidone, lurasidone, olanzapine, paliperidone, quetiapine, risperidone, ziprasidone, and zotepine cause fewer extrapyramidal problems and have many clinical applications, but they can cause metabolic disturbances. Mood stabilizers and lamotrigine are widely used for bipolar disorder. Other novel anticonvulsants such as topiramate, oxcarbazepine, gabapentin, tiagabine, pregabalin, vigabatrin, levetiracetam, and riulzole have also been tested with diverging or inconclusive results. Antidepressants are commonly used in the clinical treatment of depression and anxiety disorder. However, the mechanism of action of medications used in the treatment of psychiatric disorders remains unclear. Understanding the mechanisms of action and clarifying the diagnosis may enhance the treatment outcome in psychiatry. In this review, we analyzed clinical pharmacology data for each drug within a class and discussed clinical strategies for administering currently available antipsychotics, mood stabilizer/anticonvulsants, and antidepressants widely used for various psychiatric indications.
Subject(s)
Aripiprazole , Amines , Anticonvulsants , Antidepressive Agents , Antipsychotic Agents , Anxiety Disorders , Benzodiazepines , Bipolar Disorder , Carbamazepine , Clozapine , Cyclohexanecarboxylic Acids , Depression , Dibenzothiazepines , Dibenzothiepins , Fructose , gamma-Aminobutyric Acid , Heterocyclic Compounds, 4 or More Rings , Lurasidone Hydrochloride , Isoindoles , Isoxazoles , Nipecotic Acids , Quetiapine Fumarate , Pharmacology, Clinical , Pregabalin , Piperazines , Piperidines , Piracetam , Psychopharmacology , Pyrimidines , Quinolones , Risperidone , Sulpiride , Thiazoles , Treatment Outcome , Triazines , VigabatrinABSTRACT
Following the introduction of chlorpromazine in 1950s, for many years little progress was made in the discovery of new drugs for schizophrenia. Dopamine D2 receptors blockade was recognized as the only therapeutic target for antipsychotic drugs and formed the basis for further developments in this area. Later on enhanced efficacy of clozapine in both positive and negative symptoms in schizophrenia opened a new channel for discovery of new pharmacological treatments for this illness. Further developments looked at designing compounds, which were chemically similar to clozapine and have efficacy in both negative and positive symptomatology with diminished risk of extrapyramidal side effects. This new family of drugs, the so-called atypical antipsychotics, mainly act as serotonin- dopamine antagonists [SDA] and have shown wider spectrum of antipsychotic activity than conventional antipsychotic drugs. Their use in clinical practice is now well established and despite some limitations, clinicians prefer their use as first line treatment in schizophrenia and other related illnesses. This paper summarises current findings in the pharmacological treatment of schizophrenia and attempts to provide a review of these new drugs with future directions in this area